132 related articles for article (PubMed ID: 21054216)
1. Beneficial effects of a switch to a Lopinavir/ritonavir-containing regimen for patients with partial or no immune reconstitution with highly active antiretroviral therapy despite complete viral suppression.
Pitrak DL; Estes R; Novak RM; Linnares-Diaz M; Tschampa JM
AIDS Res Hum Retroviruses; 2011 Jun; 27(6):659-67. PubMed ID: 21054216
[TBL] [Abstract][Full Text] [Related]
2. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
[TBL] [Abstract][Full Text] [Related]
3. A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks.
Molina JM; Podsadecki TJ; Johnson MA; Wilkin A; Domingo P; Myers R; Hairrell JM; Rode RA; King MS; Hanna GJ
AIDS Res Hum Retroviruses; 2007 Dec; 23(12):1505-14. PubMed ID: 18160008
[TBL] [Abstract][Full Text] [Related]
4. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.
Orkin C; DeJesus E; Khanlou H; Stoehr A; Supparatpinyo K; Lathouwers E; Lefebvre E; Opsomer M; Van de Casteele T; Tomaka F
HIV Med; 2013 Jan; 14(1):49-59. PubMed ID: 23088336
[TBL] [Abstract][Full Text] [Related]
5. Prospective, randomized, open label trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ treatment-naive subjects with CD4+<200 cell/mm3 in Mexico.
Sierra-Madero J; Villasis-Keever A; Méndez P; Mosqueda-Gómez JL; Torres-Escobar I; Gutiérrez-Escolano F; Juárez-Kasusky I; Magana-Aquino M; Ramos-Santos C; Pérez-Saleme L; Rangel-Frausto S; Antuna-Puente B; Soto-Ramírez LE; Lima V; Belaunzarán-Zamudio F; Crabtree-Ramírez B; Montaner J
J Acquir Immune Defic Syndr; 2010 Apr; 53(5):582-8. PubMed ID: 20090545
[TBL] [Abstract][Full Text] [Related]
6. Monotherapy with Lopinavir/Ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study).
Nunes EP; Santini de Oliveira M; Merçon M; Zajdenverg R; Faulhaber JC; Pilotto JH; Ribeiro JE; Norton M; Schechter M
HIV Clin Trials; 2009; 10(6):368-74. PubMed ID: 20133267
[TBL] [Abstract][Full Text] [Related]
7. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
Ortiz R; Dejesus E; Khanlou H; Voronin E; van Lunzen J; Andrade-Villanueva J; Fourie J; De Meyer S; De Pauw M; Lefebvre E; Vangeneugden T; Spinosa-Guzman S
AIDS; 2008 Jul; 22(12):1389-97. PubMed ID: 18614861
[TBL] [Abstract][Full Text] [Related]
9. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.
Fischl MA; Collier AC; Mukherjee AL; Feinberg JE; Demeter LM; Tebas P; Giuliano M; Dehlinger M; Garren K; Brizz B; Bassett R
AIDS; 2007 Jan; 21(3):325-33. PubMed ID: 17255739
[TBL] [Abstract][Full Text] [Related]
10. Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.
Frange P; Briand N; Avettand-fenoel V; Veber F; Moshous D; Mahlaoui N; Rouzioux C; Blanche S; Chaix ML
Pediatr Infect Dis J; 2011 Aug; 30(8):684-8. PubMed ID: 21427626
[TBL] [Abstract][Full Text] [Related]
11. Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial.
Meynard JL; Bouteloup V; Landman R; Bonnard P; Baillat V; Cabie A; Kolta S; Izopet J; Taburet AM; Mercie P; Chene G; Girard PM;
J Antimicrob Chemother; 2010 Nov; 65(11):2436-44. PubMed ID: 20843990
[TBL] [Abstract][Full Text] [Related]
12. Lopinavir/ritonavir monotherapy as maintenance treatment in HIV-infected individuals with virological suppression: results from a pilot study in Brazil.
Sprinz E; Bay MB; Lazzaretti RK; Jeffman MW; Mattevi VS
HIV Med; 2008 May; 9(5):270-6. PubMed ID: 18331564
[TBL] [Abstract][Full Text] [Related]
13. Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: an open-label randomized controlled trial.
Andersson LM; Vesterbacka J; Blaxhult A; Flamholc L; Nilsson S; Ormaasen V; Sönnerborg A; Gisslén M
Scand J Infect Dis; 2013 Jul; 45(7):543-51. PubMed ID: 23294034
[TBL] [Abstract][Full Text] [Related]
14. Randomized controlled trial of once-daily tenofovir, lamivudine, and lopinavir/ritonavir versus remaining on the same regimen in virologically suppressed HIV-infected patients on their first PI-containing HAART regimen.
Loutfy MR; Ackad N; Antoniou T; Baril JG; Conway B; de Wet J; Trottier B; Kovacs CM; Thompson W; Martel AY; Trottier S; Rouleau D; Shafran SD; Rachlis A; Fraser C; Smaill F; Walmsley SL; Tseng AL; Sampalis JS
HIV Clin Trials; 2007; 8(5):259-68. PubMed ID: 17956827
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study.
Hicks C; King MS; Gulick RM; White AC; Eron JJ; Kessler HA; Benson C; King KR; Murphy RL; Brun SC
AIDS; 2004 Mar; 18(5):775-9. PubMed ID: 15075512
[TBL] [Abstract][Full Text] [Related]
16. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.
De Luca A; Cozzi-Lepri A; Antinori A; Zaccarelli M; Bongiovanni M; Di Giambenedetto S; Marconi P; Cicconi P; Resta F; Grisorio B; Ciardi M; Cauda R; Monforte Ad; ; ; ;
Antivir Ther; 2006; 11(5):609-18. PubMed ID: 16964829
[TBL] [Abstract][Full Text] [Related]
17. Long-term immunologic outcome in HAART-experienced subjects receiving lopinavir/ritonavir.
Bongiovanni M; Bini T; Casana M; Cicconi P; Tordato F; Monforte AD
AIDS Res Hum Retroviruses; 2006 Nov; 22(11):1096-105. PubMed ID: 17147495
[TBL] [Abstract][Full Text] [Related]
18. Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study.
Nozza S; Galli L; Antinori A; Chiappetta S; Mazzotta F; Zaccarelli M; Ottou S; De Battista D; Pogliaghi M; Di Pietro M; Malnati M; Ripa M; Bonora S; Lazzarin A;
Clin Microbiol Infect; 2015 May; 21(5):510.e1-9. PubMed ID: 25656621
[TBL] [Abstract][Full Text] [Related]
19. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study.
Reynes J; Trinh R; Pulido F; Soto-Malave R; Gathe J; Qaqish R; Tian M; Fredrick L; Podsadecki T; Norton M; Nilius A
AIDS Res Hum Retroviruses; 2013 Feb; 29(2):256-65. PubMed ID: 22730929
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.
Yilmaz A; Ståhle L; Hagberg L; Svennerholm B; Fuchs D; Gisslén M
Scand J Infect Dis; 2004; 36(11-12):823-8. PubMed ID: 15764168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
